


# You're looking at the answer to your recruitment problems!



It's the *Journal of the American Board of Family Practice*.  
Where you reach the best job candidates. More of them.  
More often. To find out more, just contact Classified  
Advertising at (617) 893-3800.



**The Journal of the American Board of  
Family Practice**

# CLASSIFIED ADVERTISING

Classified advertising orders, correspondence and payments should be directed to: *JABFP*, Classified Advertising, 1440 Main Street, Waltham, MA 02154.

Classified advertisements placed with *JABFP* are restricted to physician recruitment, faculty positions, CME courses/seminars, and practices for sale. All ads must relate to the medical field and are subject to approval.

Please refer to the schedule below for closing dates. Classified rate is \$1.40 per word (minimum charge of \$75.00 per ad insertion) and \$95.00 per column inch for classified display ads. Prepayment in full is required with all classified advertising. We accept American Express, VISA, or MasterCard. Confidential reply boxes are an additional \$10.00 per insertion. Responses are sent directly every Tuesday and Thursday and the box will remain open for three months.

All advertisements for employment must be nondiscriminatory and comply with all applicable laws and regulations. Ads that discriminate against applicants based on sex, age, race, religion, marital status or physical handicap will not be accepted.

**NOTE:** Our classified advertisements are all set in the same typeface and format. All ads are highlighted by geographic territory.

For more information please call (800) 635-6991 (outside MA), (617) 893-3800 (in MA). Fax # (617) 893-5003.

<i>Issue Date</i>	<i>Closing Date</i>	<i>Issue Date</i>	<i>Closing Date</i>
May-June	April 1, 1993	July-August	June 1, 1993
September-October	August 2, 1993	November-December	October 1, 1993

## MIDWEST

**MINNESOTA — FAMILY PRACTICE** — Family practice physician to join 24-member multispecialty group associated with 62-bed full service hospital. Great university community and family oriented lifestyle. Attractive financial package. Contact Verne Meyer, Delacore, 101 Park Place, Hutchinson, MN 55350, (800) 967-2711.

**FAMILY PRACTICE** — Lake Michigan community of 40,000 desires BC/BE Family Physician to join young progressive family practice group. This family-oriented community in Western Michigan offers an excellent school system and is only 30 miles from the state's 2nd-largest city, 2½ hours from Chicago and 2½ hours from the Midwest's best skiing. Salary and benefits negotiable. Send C.V. to P.O. Box 2533, Holland, MI 49422-2533.

## NORTHEAST

**UNIVERSITY OF PITTSBURGH** — The Department of Clinical Epidemiology and Family Medicine at the University of Pittsburgh School of Medicine is seeking an Assistant Professor to join a growing division of family medicine. A new medical school curriculum includes a greatly expanded role for family medicine. Primary responsibility would involve developing and coordinating a required, third year clerkship in family medicine. This is an exciting opportunity to influence the career choice of large numbers of medical students. Opportunities for clinical practice with negotiable call schedule, as well as research and scholarly activities are available. ABFP certification required. Fellowship or

previous teaching experience preferred. Salary is competitive, with excellent benefits package. Send C.V. to Seymour Grufferman, M.D., Dr. Ph.D., Professor and Chairman, University of Pittsburgh, Dept. of Clinical Epidemiology and Family Medicine, M-200 Scalfie Hall, Pittsburgh, PA 15261. The University of Pittsburgh is an Affirmative Action, Equal Opportunity Employer.

**MASSACHUSETTS** — Join a leading 580-bed community teaching hospital located within an easy commute to Boston. Be part of an integrated health care system including a children's hospital and a rehab. center. Ideal blend of practice and lifestyle. Live by the ocean and enjoy metropolitan amenities and mountain resorts. High growth area. Guaranteed salary and benefits. Ann Breilner (800) 858-4225.

## PACIFIC

**FAMILY PRACTICE** — Premier multispecialty group near Portland, Oregon has two excellent opportunities for BC/BE family practitioners. Join one of two satellite clinics in which FPs and PAs currently practice. Superb lifestyle, abundant recreational opportunities, and generous benefits package. Send CV to: Karen Stanton, c/o The Vancouver Clinic, 700 NE 87th Ave., Vancouver, WA 98664.

## SOUTHEAST

**NORTH CAROLINA** — Enjoy your family while practicing top quality medicine in mountain paradise. Seeking BC/BE family practitioner, cross-coverage with income guarantee. 81 bed acute care, state-of-the-art community hospital, with supportive staff and major specialties. Nestled in heart of Great Smoky Mountains, minutes from Appalachian Trail, rural hub to 4 metro areas. Gem mining, golfing, trout fishing, white-water rafting, hiking, 4-season-clean-air climate. 25,000 residents. Excellent schools. Send CV to Patricia Raskin-Carbonell, P.O. Box 1209, Franklin, NC 28734 or call (800) 528-5890.

**No Fee To Physician.** Nationwide opportunities for physicians of all specialties: Pharmaceutical/Biotech Industry, Single/Multi-Specialty Groups, Partnerships, HMO, Hospital-sponsored Solo, Occupational Medicine.

For confidential consideration, call or send/fax C.V. to:

**ANAPOL ENTERPRISES, INC.**

192 Lexington Avenue  
Suite 505

New York, NY 10016

800-388-6478 • 212-481-0944

Fax: 212-686-9683



Anapol Enterprises, Inc. — Just What The Doctor Ordered!

### Pick Your Family Practice

Group, Solo, Partnership ... Hospital-based or not. Urban, Suburbs, Rural. Many opportunities for 93 residents. FAX CV to Medical Staffing Assoc., 800 4 FAXDOC (800) 432-9362 or call 800 3 MSADOC (800) 367-2362.

# CARE plants the most wonderful seeds on earth.

Seeds of self-sufficiency that help starving people become healthy, productive people.  
And we do it village by village by village.  
Please help us turn cries for help  
into the laughter of hope.



**CARE**

1-800-521-CARE

# Sectral<sup>®</sup> 200 mg 400 mg CAPSULES

acebutolol HCl

The Only Cardioselective Beta Blocker  
Indicated for PVC Control

Usual starting dose	200 mg BID
Optimal PVC response	600 mg to 1200 mg per day
Use in elderly	400 mg to 800 mg per day  Doses above 800 mg per day should be avoided

## (SECTRAL - Brief Summary of prescribing information.)

**CONTRAINDICATIONS:** SECTRAL is contraindicated in: 1) persistently severe bradycardia; 2) second- and third-degree heart block; 3) overt cardiac failure; 4) cardiogenic shock. (See WARNINGS)

**WARNINGS: Cardiac Failure:** Sympathetic stimulation may be essential for support of circulation in patients with diminished myocardial contractility, and inhibition by  $\beta$ -adrenergic receptor blockade may precipitate more severe failure. Although  $\beta$ -blockers should be avoided in overt cardiac failure, SECTRAL can be used cautiously when heart failure is controlled with digitalis and/or diuretics. Digitalis and SECTRAL impair AV conduction. Withdraw SECTRAL if cardiac failure persists.

**In Patients Without a History of Cardiac Failure:** In patients with aortic or mitral valve disease or compromised left ventricular function, continued depression of the myocardium with  $\beta$ -blockers over time may lead to cardiac failure. Digitalize patients at first signs of failure, and/or give a diuretic and observe closely. Withdraw SECTRAL if cardiac failure persists.

**Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal:** Abrupt discontinuation of some  $\beta$ -blockers in coronary artery disease patients may exacerbate angina; in some cases, myocardial infarction and death have been reported. Caution such patients against interruption of therapy without a physician's advice. Even in the absence of overt ischemic heart disease, withdraw SECTRAL gradually over a period of about two weeks; observe carefully and advise patients to minimize physical activity during this time. (If desired, patients may be transferred directly to comparable doses of an alternative  $\beta$ -blocker without interruption of  $\beta$ -blocking therapy). If exacerbation of angina occurs, restart full-dose anti-anginal therapy immediately and hospitalize patient until stabilized.

**Peripheral Vascular Disease:**  $\beta$ -antagonists reduce cardiac output and can precipitate/aggravate arterial insufficiency in patients with peripheral or mesenteric vascular disease. Exercise caution and observe such patients closely for progression of arterial obstruction.

**Bronchospastic Diseases: Patients with Bronchospastic Disease Should, in General, Not Receive a  $\beta$ -Blocker.** Because of its relative  $\beta_1$ -selectivity, low doses of SECTRAL may be used cautiously in such patients who do not respond to, or cannot tolerate, alternative treatment.

Since  $\beta_1$ -selectivity is not absolute and is dose-dependent, use lowest possible dose of SECTRAL initially, preferably in divided doses. Make bronchodilator, e.g., theophylline, or a  $\beta_2$ -stimulant, available in advance with instructions for use.

**Anesthesia and Major Surgery:** The necessity/desirability of withdrawing  $\beta$ -blockers prior to major surgery is controversial; the heart's impaired ability to respond to  $\beta$ -adrenergically mediated reflex stimuli may enhance the risk of excessive myocardial depression during general anesthesia. Difficulty in restarting and maintaining the heartbeat also has been reported with  $\beta$ -blockers. If treatment is continued, take special care when using anesthetics that depress the myocardium; use lowest possible SECTRAL dose. SECTRAL, like other  $\beta$ -blockers, is a competitive inhibitor of  $\beta$ -receptor agonists, so its effects can be reversed by cautious administration of such agents (e.g., dobutamine or isoproterenol). Symptoms of excessive vagal tone (e.g., profound bradycardia, hypotension) may be corrected with atropine.

**Diabetes and Hypoglycemia:**  $\beta$ -blockers may potentiate insulin-induced hypoglycemia and mask some symptoms such as tachycardia; dizziness and sweating are usually not significantly affected. Warn diabetics of possible masked hypoglycemia.

**Thyrotoxicosis:**  $\beta$ -adrenergic blockade may mask some clinical signs (tachycardia) of hyperthyroidism. Abrupt withdrawal of SECTRAL may precipitate a thyroid storm in patients suspected of developing thyrotoxicosis.

**PRECAUTIONS: Impaired Renal or Hepatic Function:** While there are no U.S. studies, foreign published experience shows that acebutolol has been used successfully in chronic renal insufficiency. Acebutolol is excreted via the G.I. tract, but the active metabolite, diacetolol, is eliminated mainly by the kidney. A linear relationship exists between renal clearance of diacetolol and creatinine clearance ( $Cl_{cr}$ ); reduce daily dose of acebutolol by 50% when  $Cl_{cr}$  is less than 50 mL/min and by 75% when it is less than 25 mL/min. Use cautiously in patients with impaired hepatic function.

SECTRAL has been used successfully and without problems in elderly patients in U.S. clinical trials without specific dosage adjustment. However, in the elderly, lower maintenance doses may be required because bioavailability of SECTRAL and its metabolite are approximately doubled.

**Information for Patients:** Warn patients, especially those with evidence of coronary artery disease, against interruption or discontinuation of SECTRAL without physician supervision. Although cardiac failure rarely occurs in properly selected patients, advise patients to consult a physician if signs or symptoms suggestive of impending CHF, or unexplained respiratory symptoms, develop.

Warn patients of possible severe hypertensive reactions from concomitant use of  $\alpha$ -adrenergic stimulants, e.g., nasal decongestants used in OTC cold medicines and nasal drops.

**Clinical Laboratory Findings:** SECTRAL, like other  $\beta$ -blockers, has been associated with development of antinuclear antibodies (ANA). In prospective clinical trials, patients receiving SECTRAL had a dose-dependent increase in the development of positive ANA titers. Symptoms related to this laboratory abnormality were infrequent. Symptoms and ANA titers were reversible upon discontinuation of SECTRAL.

**Drug Interactions:** Catecholamine-depleting drugs may have additive effects when given with  $\beta$ -blockers. Observe patients treated with both agents closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypertensive responses have been reported from use of  $\beta$ -adrenergic antagonists with  $\alpha$ -adrenergic stimulants, including those in OTC cold remedies and vasoconstrictive nasal drops. Nonsteroidal anti-inflammatory drugs may blunt antihypertensive effects of  $\beta$ -blockers.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Chronic oral toxicity studies in rats and mice, at doses 15 times the maximum recommended (60 mg) human dose, did not indicate carcinogenic potential for SECTRAL. Diacetolol, the major metabolite in man, was without carcinogenic potential in rats at doses up to 1800 mg/kg/d. SECTRAL and diacetolol also had no mutagenic potential in the Ames Test. No significant impact on reproductive performance or fertility was found in rats following SECTRAL or diacetolol doses of up to 240 or 1000 mg/kg/d, respectively.

**Pregnancy: Teratogenic Effects:** Pregnancy Category B: No teratogenic effects were seen in rat or rabbit reproduction studies utilizing SECTRAL doses that were, respectively, approximately 31.5 and 6.8 times the maximum recommended human dose. At this dose in the rabbit, slight fetal growth retardation was noted; this was considered to be a result of maternal toxicity (evidenced by reduced food intake, lowered rate of body weight gain, mortality). Diacetolol studies (doses up to 450 mg/kg/d in rabbits and up to 1800 mg/kg/d in rats) showed no evidence of fetal harm other than a significant elevation in postimplantation loss with 450 mg/kg/d, a level at which food consumption and body weight gain were reduced in rabbit dams; there was a nonstatistically significant increase in incidence of bilateral cataract in rat fetuses from dams treated with 1800 mg/kg/d. There are no adequate and well-controlled trials in pregnant women; SECTRAL should be used during pregnancy only if potential benefit justifies risk to the fetus.

**Nonteratogenic Effects:** Human studies indicate that acebutolol and diacetolol cross the placenta. Neonates of mothers who received acebutolol during pregnancy have reduced birth weight, decreased blood pressure, and decreased heart rate.

**Labor and Delivery:** Effect on labor and delivery in pregnant women is unknown. Animal studies have shown no effect of SECTRAL on the usual course of labor and delivery.

**Nursing Mothers:** Acebutolol and diacetolol appear in breast milk (milk:plasma ratio of 7.1 and 12.2, respectively). Use in nursing mothers is not recommended.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** SECTRAL is well tolerated in properly selected patients. Most adverse effects have been mild, not required therapy discontinuation, and tended to decrease as treatment duration increases.

The incidence of treatment-related side effects (volunteered and elicited) derived from U.S. controlled clinical trials in patients with hypertension, angina and arrhythmia follows. Numbers represent percentage incidence for SECTRAL (N=1002) versus placebo (N=314), respectively.

**Cardiovascular:** Chest pain 2%, 1%; Edema 2%, 1%. **CNS:** Depression 2%, 1%; Dizziness 6%, 2%; Fatigue 11%, 4%; Headache 6%, 4%; Insomnia 3%, 1%; Abnormal dreams 2%, 1%. **Dermatologic:** Rash 2%, 1%; **Gastrointestinal:** Constipation 4%, 0%; Diarrhea 4%, 1%; Dyspepsia 4%, 1%; Flatulence 3%, 1%; Nausea 4%, 0%. **Genitourinary:** Micturition (frequency) 3%, <1%. **Musculoskeletal:** Arthralgia 2%, 2%; Myalgia 2%, 0%. **Respiratory:** Cough 1%, 0%; Dyspnea 4%, 2%; Rhinitis 2%, <1%. **Special Senses:** Abnormal Vision 2%, 0%.

The following selected (potentially important) side effects were seen in up to 2% of SECTRAL patients: **Cardiovascular:** hypotension, bradycardia, heart failure. **CNS:** anxiety, hyper/hypoesthesia, impotence. **Skin:** pruritus. **Gastrointestinal:** vomiting, abdominal pain. **Genitourinary:** dysuria, nocturia. **Liver and Biliary:** small number of reported cases of liver abnormalities (increased SGOT, SGPT, LDH). In some cases, increased bilirubin or alkaline phosphatase, fever, malaise, dark urine, anorexia, nausea, headache, and/or other symptoms have been reported. In some cases, symptoms and signs were confirmed by rechallenge. Abnormalities were reversible upon drug cessation. **Musculoskeletal:** back and joint pain. **Respiratory:** pharyngitis, wheezing. **Special Senses:** conjunctivitis, dry eye, eye pain. **Autoimmune:** extremely rare reports of systemic lupus erythematosus.

Incidence of drug-related adverse effects (volunteered and solicited) based on SECTRAL dose is shown below. (Data from 266 hypertensive patients treated for 3 months on a constant dose.)

Body System	400 mg/day (N=132)	800 mg/day (N=63)	1200 mg/day (N=71)
Cardiovascular	5%	2%	1%
Gastrointestinal	3%	3%	7%
Musculoskeletal	2%	3%	4%
Central Nervous System	9%	13%	17%
Respiratory	1%	5%	6%
Skin	1%	2%	1%
Special Senses	2%	2%	6%
Genitourinary	2%	3%	1%

**Potential Adverse Effects:** Certain adverse effects not listed above have been reported with other  $\beta$ -blocking agents and should be considered as potential adverse effects of SECTRAL.

**CNS:** Reversible mental depression progressing to catatonia, an acute syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

**Cardiovascular:** Intensification of AV block (see **CONTRAINDICATIONS**).

**Allergic:** Erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress.

**Hematologic:** Agranulocytosis, nonthrombocytopenic and thrombocytopenic purpura.

**Gastrointestinal:** Mesenteric arterial thrombosis, ischemic colitis.

**Miscellaneous:** Reversible alopecia, Peyronie's disease. The oculomucocutaneous syndrome associated with praxolol has not been reported with SECTRAL.

**Keep at room temperature. Approximately 25°C (77°F).**

3482-6 8/13/92

## Reference:

1. Data on file, Wyeth-Ayerst Laboratories.